Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linda Henry

Showing results (131-140 of 278) with videos related to

Pageof 28
Sort By:
Hepatology Communications|February 7, 2018
Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver diseaseZobair M Younossi, Maria Stepanova, Nila Rafiq, et al.
Journal of Clinical and Experimental Hepatology|April 9, 2026
Self-Reported Cognitive Function in Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Post-hoc Analysis of the MAESTRO Resmetirom TrialsZobair M Younossi, Fatema Nader, Dominic Labriola, et al.
Hepatology (Baltimore, Md.)|August 15, 2015
Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009Zobair M Younossi, Munkhzul Otgonsuren, Linda Henry, et al.
Hepatology Communications|September 24, 2021
Poor Awareness of Liver Disease Among Adults With NAFLD in the United StatesSaleh A Alqahtani, James M Paik, Rakesh Biswas, et al.
Gut|August 2, 2019
Epidemiology of chronic liver diseases in the USA in the past three decadesZobair M Younossi, Maria Stepanova, Youssef Younossi, et al.
Hepatology (Baltimore, Md.)|January 10, 2023
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic reviewZobair M Younossi, Pegah Golabi, James M Paik, et al.
Hepatology (Baltimore, Md.)|April 1, 2022
Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?Zobair M Younossi, James M Paik, Reem Al Shabeeb, et al.
Clinical and Translational Gastroenterology|March 16, 2018
Increasing co-morbidities in chronic hepatitis B patients: experience in primary care and referral practices during 2000-2015Anne Liu, An Le, Jian Zhang, et al.
Hepatology Communications|February 27, 2026
Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosisZobair M Younossi, Fatema Nader, Dominic Labriola, et al.
Hepatology (Baltimore, Md.)|September 9, 2024
Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosisZobair M Younossi, Maria Stepanova, Andrei Racila, et al.
Pageof 28

Showing results (131-140 of 278) with videos related to

Sort By:
Pageof 28
Hepatology Communications|February 7, 2018
Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver diseaseZobair M Younossi, Maria Stepanova, Nila Rafiq, et al.
Journal of Clinical and Experimental Hepatology|April 9, 2026
Self-Reported Cognitive Function in Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Post-hoc Analysis of the MAESTRO Resmetirom TrialsZobair M Younossi, Fatema Nader, Dominic Labriola, et al.
Hepatology (Baltimore, Md.)|August 15, 2015
Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009Zobair M Younossi, Munkhzul Otgonsuren, Linda Henry, et al.
Hepatology Communications|September 24, 2021
Poor Awareness of Liver Disease Among Adults With NAFLD in the United StatesSaleh A Alqahtani, James M Paik, Rakesh Biswas, et al.
Gut|August 2, 2019
Epidemiology of chronic liver diseases in the USA in the past three decadesZobair M Younossi, Maria Stepanova, Youssef Younossi, et al.
Hepatology (Baltimore, Md.)|January 10, 2023
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic reviewZobair M Younossi, Pegah Golabi, James M Paik, et al.
Hepatology (Baltimore, Md.)|April 1, 2022
Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?Zobair M Younossi, James M Paik, Reem Al Shabeeb, et al.
Clinical and Translational Gastroenterology|March 16, 2018
Increasing co-morbidities in chronic hepatitis B patients: experience in primary care and referral practices during 2000-2015Anne Liu, An Le, Jian Zhang, et al.
Hepatology Communications|February 27, 2026
Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosisZobair M Younossi, Fatema Nader, Dominic Labriola, et al.
Hepatology (Baltimore, Md.)|September 9, 2024
Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosisZobair M Younossi, Maria Stepanova, Andrei Racila, et al.
Pageof 28